US OptionsDetailed Quotes
AVPT241220C16000
- 2.00
- -0.50-20.00%
15min DelayClose Nov 27 16:00 ET
2.00High1.90Low
1.90Open2.50Pre Close2 Volume101 Open Interest16.00Strike Price390.00Turnover58.57%IV1.01%PremiumDec 20, 2024Expiry Date1.82Intrinsic Value100Multiplier22DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type0.7982Delta0.1092Gamma8.19Leverage Ratio-0.0178Theta0.0074Rho6.54Eff Leverage0.0124Vega
AvePoint Stock Discussion
• $Anaplan (PLAN.US)$ +28.2% (to be acquired by Thoma Bravo for $66.00 per share)
• $Guess (GES.US)$ +5.04% (entered into an accelerated share repurchase agreement to repurchase $175 mln of its common stock)
• $Membership Collective (MCG.US)$ +2.8% (authorizes stock repurchase program to repurchase up to $50 mln of the Company's Class A common stock)
• $Sorrento Therapeutics (SRNE.US)$ +2.3% (reports promising results with a universal...
• $Air Products & Chemicals (APD.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $275
• $Associated Banc (ASB.US)$: Wells Fargo Upgrades to Overweight from Equal Weight - PT $28 (from $26)
• $Armstrong World Industries (AWI.US)$: Jefferies Upgrades to Buy from Hold - PT $111 (from $101)
• $BlackBerry (BB.US)$: RBC Capital Upgrades to Sector Perform from Underperform - PT $7
• $Commerce Bancshares (CBSH.US)$: Wells Fargo Upgrades to Equal Weight from...
From what we know the new strain seems more resistant against existing vaccines. That would suggest that we need new vaccines to address this new variant.
How could we translate this hypothesis into a stock position?
I’m not familiar with the pharma industry and don’t know how things work in pharma. But from what I know you usually have small startups innovating and coming up with vaccine technologies and then larger corporations acquiring them.
So how would we expect biotech stocks to behave as the new COVID strain becomes priced into the market?
Gonna wait a long time to touch $11💩
$AvePoint (AVPT.US)$
gonna hit all time highs!
No comment yet